Hematopoietic stem cell transplantation for metachromatic leukodystrophy

Laura Lorioli, Alessandra Biffi

Research output: Contribution to journalArticle

Abstract

Metachromatic leukodystrophy (MLD) is a rare, fatal, inherited lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA). The enzymatic defect results in the accumulation of the ARSA substrate, mainly in myelin forming cells, leading to progressive demyelination and dysfunction in the CNS and peripheral nervous system. The severity of the disease and the absence of approved treatments stimulate testing innovative therapeutic strategies.Areas covered: Among diverse experimental approaches, hematopoietic stem cell (HSC) transplantation (HSCT) from healthy compatible donors, and very recently, gene therapy based on transplantation of autologous HSCs transduced with a lentiviral vector encoding for the ARSA cDNA have been applied to MLD patients. State of the development of these HSC-based strategies is here analyzed, based on a review of the scientific literature, focusing on the outcomes of allogeneic HSCT, and on its potential clinical benefit and limitations.Expert opinion: HSC-based approaches would require the evaluation of long-term follow-up on neurological and transplant-related outcomes of larger cohorts of patients, in order to rationally define indication to treatment for MLD patients.

Original languageEnglish
Pages (from-to)911-919
Number of pages9
JournalExpert Opinion on Orphan Drugs
Volume3
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Metachromatic Leukodystrophy
Hematopoietic Stem Cell Transplantation
Cerebroside-Sulfatase
Hematopoietic Stem Cells
Autologous Transplantation
Homologous Transplantation
Peripheral Nervous System
Expert Testimony
Demyelinating Diseases
Myelin Sheath
Genetic Therapy
Therapeutics
Complementary DNA
Tissue Donors
Transplants

Keywords

  • Gene therapy
  • hematopoietic stem cells
  • metachromatic leukodystrophy
  • transplantation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Hematopoietic stem cell transplantation for metachromatic leukodystrophy. / Lorioli, Laura; Biffi, Alessandra.

In: Expert Opinion on Orphan Drugs, Vol. 3, No. 8, 01.08.2015, p. 911-919.

Research output: Contribution to journalArticle

Lorioli, Laura ; Biffi, Alessandra. / Hematopoietic stem cell transplantation for metachromatic leukodystrophy. In: Expert Opinion on Orphan Drugs. 2015 ; Vol. 3, No. 8. pp. 911-919.
@article{dea3e954da0142cf9899c0a06c7619f4,
title = "Hematopoietic stem cell transplantation for metachromatic leukodystrophy",
abstract = "Metachromatic leukodystrophy (MLD) is a rare, fatal, inherited lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA). The enzymatic defect results in the accumulation of the ARSA substrate, mainly in myelin forming cells, leading to progressive demyelination and dysfunction in the CNS and peripheral nervous system. The severity of the disease and the absence of approved treatments stimulate testing innovative therapeutic strategies.Areas covered: Among diverse experimental approaches, hematopoietic stem cell (HSC) transplantation (HSCT) from healthy compatible donors, and very recently, gene therapy based on transplantation of autologous HSCs transduced with a lentiviral vector encoding for the ARSA cDNA have been applied to MLD patients. State of the development of these HSC-based strategies is here analyzed, based on a review of the scientific literature, focusing on the outcomes of allogeneic HSCT, and on its potential clinical benefit and limitations.Expert opinion: HSC-based approaches would require the evaluation of long-term follow-up on neurological and transplant-related outcomes of larger cohorts of patients, in order to rationally define indication to treatment for MLD patients.",
keywords = "Gene therapy, hematopoietic stem cells, metachromatic leukodystrophy, transplantation",
author = "Laura Lorioli and Alessandra Biffi",
year = "2015",
month = "8",
day = "1",
doi = "10.1517/21678707.2015.1062754",
language = "English",
volume = "3",
pages = "911--919",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for metachromatic leukodystrophy

AU - Lorioli, Laura

AU - Biffi, Alessandra

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Metachromatic leukodystrophy (MLD) is a rare, fatal, inherited lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA). The enzymatic defect results in the accumulation of the ARSA substrate, mainly in myelin forming cells, leading to progressive demyelination and dysfunction in the CNS and peripheral nervous system. The severity of the disease and the absence of approved treatments stimulate testing innovative therapeutic strategies.Areas covered: Among diverse experimental approaches, hematopoietic stem cell (HSC) transplantation (HSCT) from healthy compatible donors, and very recently, gene therapy based on transplantation of autologous HSCs transduced with a lentiviral vector encoding for the ARSA cDNA have been applied to MLD patients. State of the development of these HSC-based strategies is here analyzed, based on a review of the scientific literature, focusing on the outcomes of allogeneic HSCT, and on its potential clinical benefit and limitations.Expert opinion: HSC-based approaches would require the evaluation of long-term follow-up on neurological and transplant-related outcomes of larger cohorts of patients, in order to rationally define indication to treatment for MLD patients.

AB - Metachromatic leukodystrophy (MLD) is a rare, fatal, inherited lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA). The enzymatic defect results in the accumulation of the ARSA substrate, mainly in myelin forming cells, leading to progressive demyelination and dysfunction in the CNS and peripheral nervous system. The severity of the disease and the absence of approved treatments stimulate testing innovative therapeutic strategies.Areas covered: Among diverse experimental approaches, hematopoietic stem cell (HSC) transplantation (HSCT) from healthy compatible donors, and very recently, gene therapy based on transplantation of autologous HSCs transduced with a lentiviral vector encoding for the ARSA cDNA have been applied to MLD patients. State of the development of these HSC-based strategies is here analyzed, based on a review of the scientific literature, focusing on the outcomes of allogeneic HSCT, and on its potential clinical benefit and limitations.Expert opinion: HSC-based approaches would require the evaluation of long-term follow-up on neurological and transplant-related outcomes of larger cohorts of patients, in order to rationally define indication to treatment for MLD patients.

KW - Gene therapy

KW - hematopoietic stem cells

KW - metachromatic leukodystrophy

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84937390306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937390306&partnerID=8YFLogxK

U2 - 10.1517/21678707.2015.1062754

DO - 10.1517/21678707.2015.1062754

M3 - Article

AN - SCOPUS:84937390306

VL - 3

SP - 911

EP - 919

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 8

ER -